ai platform News
-
CDMO makes an AI and drug discovery play in latest, small-time acquisition
The CDMO outfit iBio has netted a deal that sees it gain access to an AI-based platform as well as new therapeutic candidates as it looks to dive further into drug discovery. iBio closed on acquiring several assets from the San Diego-based biotech RubrYc Therapeutics, snapping up several oncology programs. The cost includes a $1 million upfront payment as well as the ability of RubrYc’s ...
By Ibio, Inc.
-
Aidoc Showcases Full Ai Care Coordination Suite At International Stroke Conference 2022
AI-powered neuroscience solutions for intracranial hemorrhage, ischemic stroke, cervical spine fractures, on display at ISC 2022, New Orleans, February 9-11, Booth #801 New York, February 8, 2022 – Aidoc, the leading provider of healthcare AI solutions, will be delivering a live demonstration of its comprehensive AI care coordination suite at ISC 2022, February 9-11, in New Orleans, Booth ...
By Aidoc
-
Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment
Insilico Medicine, a clinical-stage end-to-end artificial intelligence (AI)-driven drug discovery company, today announced its nomination of a novel preclinical candidate (PCC) targeting 3C-like (3CL) protease for the treatment of COVID-19. Insilico's PCC is an orally available 3CL protease inhibitor with a novel structure generated using Insilico's AI platform. The compound can be efficiently ...
-
BenevolentAI To Present At The 40th Annual JP Morgan Healthcare Conference
London, 07 January, 2022BenevolentAI, a leading clinical-stage AI drug discovery company, today announced that Joanna Shields, Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Monday, 10th January, 2022 at 8.00am ET / 13.00 GMT. About BenevolentAI BenevolentAI is a leading, clinical-stage AI drug discovery company. Through the ...
By Benevolent
-
Optibrium expands operations in North America for AI and computational drug discovery technologies
Optibrium, a leading developer of software and artificial intelligence (AI) solutions for drug discovery, today announced the opening of its US subsidiary, Optibrium Inc., and the promotion of Dr Tamsin Mansley to President of the new subsidiary to lead its US-based team and business operations. The opening strengthens the Company’s direct sales, technical and application support for new ...
-
PercayAI and Saint Louis University Partner to Accelerate AI Adoption across Biomedical Sciences Research
Biotech firm PercayAI and Saint Louis University (SLU) announced a partnership today to provide SLU researchers with access to PercayAI’s augmented intelligence (AI) drug discovery platform. One of the primary components of the PercayAI platform is CompBio™, software co-developed with the Genome Technology Access Center at the McDonnell Genome Institute (GTAC@MGI) at Washington ...
By PercayAI
-
Deep Genomics Raises $180M in Series C Financing
Company expands AI discovery platform for ‘Programmable’ RNA therapeutics and supports advancement of its portfolio into the clinic Oversubscribed round led by SoftBank Vision Fund 2, with CPP Investments, Fidelity Management & Research Company LLC, Alexandria Venture Investments, Amplitude Ventures, Khosla Ventures, Magnetic Ventures, and True Ventures Deep Genomics, the ...
-
TeraRecon Appoints Sinan Batman CTO
Advanced visualization and AI leader TeraRecon today announced the appointment of Sinan Batman as Chief Technology Officer, responsible for developing next-gen, AI-based advanced visualization and clinical workflow application technologies. "Sinan shares our drive for better patient outcomes and value through out-of-the-box solutions for streamlined efficiency and effectiveness," said Romesh ...
-
Bright Path Laboratories selects TrackWise Digital QMS
Sparta Systems, provider of Quality Management System (QMS) platforms TrackWise and TrackWise Digital, has announced that Bright Path Laboratories, a leader in continuous-flow reactor technology, has selected TrackWise Digital as their QMS of the future. Bright Path Labs will implement TrackWise Digital’s platform for end-to-end quality management, document management, and training ...
-
Arterys Partners With Combinostics to Accelerate Accurate and Consistent Evaluations of Patients With Neurodegenerative Disease and Multiple Sclerosis
SAN FRANCISCO, November 26, 2021 (Newswire.com) - Arterys, the world's leading vendor neutral AI platform, today announced its partnership with Combinostics to make their AI imaging solution, cNeuro® available on the Arterys Platform. This partnership enables Arterys to have the most comprehensive Neuro AI suite on the market covering a broad set of applications in neuroradiology. Arterys ...
By Arterys Inc.
-
Optibrium strengthens global AI drug discovery software operations with three key appointments
Michelle Harrison appointed as Head of Strategic Marketing; Chris Khoury and Imran Ghauri join to boost Optibrium’s business development team. UK and US-based appointments with proven AI and life science expertise will support the next phase of commercial growth for Optibrium’s computational drug discovery technologies. Optibrium, a leading developer of software and artificial ...
-
CytoReason Announces Collaboration with Ferring to Identify Novel Therapeutic Targets in Inflammatory Bowel Disease Using AI Technology
TEL AVIV, Israel, May 19, 2021 /PRNewswire/ -- CytoReason, an Israeli company developing a computational model of the human body for faster drug discovery and development, today announced a collaboration with Swiss multinational biopharmaceutical company, Ferring Pharmaceuticals, which aims to establish new treatment options for patients with inflammatory bowel disease (IBD). This is the first ...
By CytoReason
-
Exscientia enters $70M collaboration to develop anti-viral therapeutics against Coronavirus and other viruses with pandemic potential
Four-year agreement with Bill & Melinda Gates Foundation to discover and develop small molecule therapeutics with less susceptibility to variants and greater patient access than current approaches -- Exscientia to use leading AI platform and in-house drug expertise to discover and develop five phase 1-ready assets; Gates Foundation to contribute sector expertise in antivirals and global ...
By Exscientia
-
Aidoc Partners With Novant Health, Providing Imaging Ai To Expedite Treatment For Patients In The Emergency Department
Novant Health’s integration of Aidoc’s AI solutions, amid the latest wave of the Omicron variant, expands upon its existing slate of innovative technologies designed to improve delivery of patient care and outcomes Aidoc, the leading provider of enterprise-grade AI solutions for medical imaging, announces a partnership with Novant Health, a health network of over 1,800 physicians ...
By Aidoc
-
Beijing Tide Pharmaceutical and Insilico Medicine enter into an agreement for cancer therapy
Beijing Tide Pharmaceutical Co., Ltd. (Tide), a subsidiary of Sino Biopharmaceutical Limited, and Insilico Medicine, an artificial intelligence company developing end-to-end drug discovery pipelines, announced today that they are entering a collaboration, applying artificial intelligence (AI) technology to drug discovery, to jointly accelerate the process for multiple types of cancer treatment. ...
-
AIDOC and IMBIO partner to provide an industry first ai solution to prioritize suspected pulmonary embolism and automatically calculate RV/LV ratio
Aidoc, the leading provider of enterprise AI solutions, and Imbio, a leading provider of medical image analysis for pulmonary and cardiothoracic diseases, announced today a partnership intended to provide the world’s first end-to-end AI solution for pulmonary embolism (PE), with the goal of ultimately improving efficiency and quality of pulmonary embolism detection and treatment. ...
By Aidoc
-
Healx launches partnership with Ataxia UK and FARA to find treatments for rare neurodegenerative condition
Ataxia UK is the leading charity in the United Kingdom for people affected by ataxia - an umbrella term for a group of neurological disorders that target the nervous system and affect balance, coordination and speech. FARA (Friedreich’s Ataxia Research Alliance) is a non-profit organisation in the US, dedicated to supporting research into treatments and cures for Friedreich’s ataxia, ...
By Healx Ltd.
-
CytoReason Expands Its Reach in Asia, Forging Commercial Alliance with Helixrus to Leverage Machine Learning in Drug Development for Korean Drugmakers
TEL AVIV, Israel and SEOUL, South Korea, April 12, 2022 /PRNewswire/ -- CytoReason, a leading developer of computational disease models for efficient drug discovery and development, announced today the signing of a commercial partnership with Helixrus, a leading Korean company focused on biological big data and multi-omics. The partnership will see Helixrus represent CytoReason's unique AI ...
By CytoReason
-
CytoReason Collaborates with Sanofi, Using its AI Technology to Gain Better Understanding of Disease Mechanisms
TEL AVIV, Israel, June 17, 2021 /PRNewswire/ -- CytoReason, an AI company developing a computational disease model of the human body for clinical drug development, today announced the initiation of a project with French global biopharmaceutical company Sanofi, which will utilize its cell-centered models and deconvolution techniques to suggest mechanistic insights for each asthma endotype. The ...
By CytoReason
-
Atomwise and FutuRx Launch A2i Therapeutics - A New Immuno-Oncology Company Funded by Leading Biopharma VCs and the Israeli Innovation Authority
Atomwise, the leader in using artificial intelligence (AI) for small-molecule drug discovery, announced today a partnership with FutuRx, a recognized Israeli-based biotechnology incubator focused on innovative, early-stage therapeutic technologies. The collaboration will serve as the first introduction of Atomwise’s AtomNet® platform for AI-based drug discovery to a growing biotech ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you